Uremic Pruritus Pipeline Shows Rapid Progress in Clinical Trials
14 Jul 2021
AntibodySmall molecular drugPriority Review
Los Angeles, USA , July 13, 2021 (GLOBE NEWSWIRE) -- Uremic Pruritus Pipeline Shows Rapid Progress in Clinical Trials
Around 6+ key companies are developing Uremic Pruritus therapies. The drug candidate Difelikefalin by Cara Therapeutics has been accepted and granted priority review by the US Food and Drug Administration.
DelveInsight’s “Uremic Pruritus Pipeline Insight” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Uremic Pruritus pipeline landscapes. It comprises Uremic Pruritus pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Uremic Pruritus therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Uremic Pruritus pipeline products.
Some of the key takeaways from the Uremic Pruritus Pipeline Report
Get an overview of pipeline landscape @ Uremic Pruritus Clinical Trials Analysis
Uremic Pruritus is also called chronic kidney disease-associated pruritus (CKD-associated pruritus). Uremia refers to excessive urea in the blood and occurs when both kidneys stop working. Pruritus, or itch, is a common problem for patients with chronic renal failure or end-stage renal disease.
Uremic Pruritus Emerging Drugs
HSK 21542 is an opioid kappa receptor agonist being developed and investigated in Phase II clinical trial to treat Uremic pruritus by Haisco Pharmaceutical. The main objective is to evaluate the safety, pharmacokinetics, and efficacy of HSK21542 injection in subjects undergoing hemodialysis. It is being investigated to be administered via the parenteral route of administration.
Lumos Therapeutics’ LT 5001 is a drug candidate for Uremic Pruritus. The drug has secured Taiwan FDA approval for conducting an Ib/2 trial. It is being developed to be applied topically. It is a partial mu-opioid antagonist and kappa-opioid agonist. The formulation is considered to have the ability to modulate opioid receptors on immune cells and sensory nerves.
EP547 is an MRGPRX4 targeted product candidate to treat cholestatic and uremic pruritus being evaluated by Escient Pharmaceuticals. The Phase I/Ib trial of EP547 is a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of EP547 in healthy subjects and subjects with cholestatic or uremic pruritus.
For further information, refer to the detailed report @ Uremic Pruritus Pipeline Therapeutics
Scope of Uremic Pruritus Pipeline Drug Insight
· Uremic Pruritus Therapies Late-stage (Phase III) · Uremic Pruritus Therapies Mid-stage (Phase II)· Uremic Pruritus Therapies Early-stage (Phase I) · Uremic Pruritus Pre-clinical stage and Discovery candidates · Discontinued and Inactive candidates
· Opioid kappa receptor agonists · Kappa-opioid receptor agonist
· Natural metabolites· Monoclonal Antibody · Small molecule
· Intravenous · Oral· Subcutaneous · Intramuscular
· Monotherapy· Combination· Mono/Combination
Key Questions regarding Current Uremic Pruritus Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
Table of Contents
Get a customized pipeline report @ Uremic Pruritus Drugs Pipeline Report
Related Reports
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
Organizations
Indications
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.